GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
Contenu indisponible. Consultez la source originale.
GSK licenses linerixibat for liver disease itch to Alfasigma for $300M upfront
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.